Drug intelligence / Profile preview

TPB15

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

TPB15 is an orally active and potent inhibitor of the Hedgehog (Hh) signaling pathway. It has been shown to induce cell cycle arrest and apoptosis in MDA-MB-468 cells, a triple-negative breast cancer (TNBC) cell line. Preclinical studies indicate that TPB15 demonstrates significant efficacy and safety both in vitro and in vivo, making it a promising candidate for the treatment of TNBC[1][10].

Targets

CYP3A4 (Cytochrome P450 3A4)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)SMO (Smoothened)

Beyond the preview

Go deeper on TPB15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPB15.

Explore the full profile